Hsbc Holdings PLC Sells 4,961 Shares of Halozyme Therapeutics, Inc. $HALO

Hsbc Holdings PLC decreased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 51.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,654 shares of the biopharmaceutical company’s stock after selling 4,961 shares during the period. Hsbc Holdings PLC’s holdings in Halozyme Therapeutics were worth $297,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in HALO. Stifel Financial Corp lifted its stake in Halozyme Therapeutics by 79.7% during the fourth quarter. Stifel Financial Corp now owns 30,768 shares of the biopharmaceutical company’s stock worth $1,471,000 after purchasing an additional 13,647 shares during the period. AXA S.A. lifted its stake in Halozyme Therapeutics by 22.1% during the fourth quarter. AXA S.A. now owns 131,891 shares of the biopharmaceutical company’s stock worth $6,306,000 after purchasing an additional 23,835 shares during the period. Algert Global LLC bought a new position in Halozyme Therapeutics during the fourth quarter worth about $521,000. Baird Financial Group Inc. lifted its stake in Halozyme Therapeutics by 2.0% during the fourth quarter. Baird Financial Group Inc. now owns 11,119 shares of the biopharmaceutical company’s stock worth $532,000 after purchasing an additional 221 shares during the period. Finally, Captrust Financial Advisors raised its stake in shares of Halozyme Therapeutics by 24.3% in the fourth quarter. Captrust Financial Advisors now owns 29,862 shares of the biopharmaceutical company’s stock valued at $1,428,000 after acquiring an additional 5,829 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Performance

HALO stock opened at $74.82 on Thursday. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.01. The company has a 50 day moving average price of $61.93 and a 200 day moving average price of $59.59. Halozyme Therapeutics, Inc. has a fifty-two week low of $42.01 and a fifty-two week high of $74.94. The stock has a market capitalization of $8.75 billion, a PE ratio of 17.12, a price-to-earnings-growth ratio of 0.42 and a beta of 1.19.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, topping analysts’ consensus estimates of $1.23 by $0.31. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The firm had revenue of $325.72 million during the quarter, compared to analyst estimates of $282.66 million. During the same quarter in the previous year, the business earned $0.91 EPS. The business’s quarterly revenue was up 40.8% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 4,000 shares of Halozyme Therapeutics stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $73.68, for a total transaction of $294,720.00. Following the completion of the sale, the director owned 46,952 shares of the company’s stock, valued at approximately $3,459,423.36. The trade was a 7.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $63.51, for a total transaction of $1,270,200.00. Following the sale, the chief executive officer directly owned 733,719 shares of the company’s stock, valued at $46,598,493.69. This represents a 2.65% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 84,000 shares of company stock valued at $4,827,320 in the last ninety days. Company insiders own 2.90% of the company’s stock.

Wall Street Analysts Forecast Growth

HALO has been the subject of a number of research analyst reports. Leerink Partners cut shares of Halozyme Therapeutics from a “market perform” rating to an “underperform” rating and set a $47.00 target price for the company. in a research note on Tuesday, May 13th. JPMorgan Chase & Co. lifted their target price on shares of Halozyme Therapeutics from $60.00 to $63.00 and gave the company a “neutral” rating in a research note on Thursday, August 7th. Morgan Stanley lifted their target price on shares of Halozyme Therapeutics from $75.00 to $80.00 and gave the company an “overweight” rating in a research note on Monday, August 18th. Benchmark cut shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 7th. Finally, JMP Securities lifted their target price on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the company a “market outperform” rating in a research note on Wednesday, August 6th. Four equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $67.11.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.